Exact Mass: 337.0038

Exact Mass Matches: 337.0038

Found 99 metabolites which its exact mass value is equals to given mass value 337.0038, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AC - Oxicams D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D004791 - Enzyme Inhibitors

famotidine

Famotidine (Pepcid)

C8H15N7O2S3 (337.0449)

A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BA - H₂-receptor antagonists C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Famotidine

3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide

C8H15N7O2S3 (337.0449)

Famotidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). It is commonly marketed by Merck under the trade names Pepcidine and Pepcid. [HMDB] Famotidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). It is commonly marketed by Merck under the trade names Pepcidine and Pepcid. A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BA - H₂-receptor antagonists D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Tenoxicam

(3Z)-3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-2H,3H,4H-1λ⁶-thieno[2,3-e][1,2]thiazine-1,1,4-trione

C13H11N3O4S2 (337.0191)

Tenoxicam is only found in individuals that have used or taken this drug. It is an antiinflammatory agent with analgesic and antipyretic properties, and is used to treat osteoarthritis and control acute pain.The antiinflammatory effects of tenoxicam may result from the inhibition of the enzyme cycooxygenase and the subsequent peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, their inhibition accounts for the peripheral analgesic effects of tenoxicam. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss. M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AC - Oxicams D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D004791 - Enzyme Inhibitors

5-Carboxy-lumiracoxib

3-{[2-(carboxymethyl)-4-methylphenyl]amino}-4-chloro-2-fluorobenzoic acid

C16H13ClFNO4 (337.0517)

5-Carboxy-lumiracoxib is a metabolite of lumiracoxib. Lumiracoxib is a COX-2 selective inhibitor non-steroidal anti-inflammatory drug, manufactured by Novartis and still sold in few countries, including Mexico, Ecuador and the Dominican Republic, under the trade name Prexige (sometimes misquoted as Prestige by the media). Lumiracoxib has several distinctive features. (Wikipedia)

1H-Imidazole-1-ethanol, 2-nitro-alpha-((2,2,2-trifluoro-1-(trifluoromethyl)ethoxy)methyl)-

C9H9F6N3O4 (337.0497)

Fenquizone

7-chloro-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinazoline-6-sulfonamide

C14H12ClN3O3S (337.0288)

C - Cardiovascular system > C03 - Diuretics > C03B - Low-ceiling diuretics, excl. thiazides > C03BA - Sulfonamides, plain C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D045283 - Natriuretic Agents > D004232 - Diuretics

Sudoxicam

4-hydroxy-2-methyl-1,1-dioxo-N-(1,3-thiazol-2-yl)-2H-1lambda6,2-benzothiazine-3-carboxamide

C13H11N3O4S2 (337.0191)

4-(2,5-Dihydroxypyrrol-1-yl)-N-(1,3-thiazol-2-yl)benzenesulfonamide

4-(2,5-Dihydroxy-1H-pyrrol-1-yl)-N-(1,3-thiazol-2-yl)benzene-1-sulphonamide

C13H11N3O4S2 (337.0191)

MLS000833764

C11H13Cl2N3OS2 (336.9877)

Bio5G8

C12H7Cl2F2NO2S (336.9543)

Oprea1_856316

C15H13Cl2N3O2 (337.0385)

ZINC141255

C13H18Cl3N3O (337.0515)

2-Bromo-6,8-dihydroxy-7-propyl-9H-pyrrolo[2,1-b][1,3]benzoxazine-9-one

C14H12BrNO4 (336.995)

4-[(2-methoxycarbonyl-5-thiophen-2-ylthiophen-3-yl)amino]-4-oxobut-2-enoic acid

C14H11NO5S2 (337.0079)

Pepcid

famotidine

C8H15N7O2S3 (337.0449)

CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2002; ORIGINAL_PRECURSOR_SCAN_NO 2000 A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BA - H₂-receptor antagonists C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1942; ORIGINAL_PRECURSOR_SCAN_NO 1939 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1950; ORIGINAL_PRECURSOR_SCAN_NO 1949 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1959; ORIGINAL_PRECURSOR_SCAN_NO 1957 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 1977; ORIGINAL_PRECURSOR_SCAN_NO 1975 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2003; ORIGINAL_PRECURSOR_SCAN_NO 2000 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4186; ORIGINAL_PRECURSOR_SCAN_NO 4184 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4210; ORIGINAL_PRECURSOR_SCAN_NO 4209 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4236; ORIGINAL_PRECURSOR_SCAN_NO 4235 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4229; ORIGINAL_PRECURSOR_SCAN_NO 4227 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4226; ORIGINAL_PRECURSOR_SCAN_NO 4225 CONFIDENCE standard compound; INTERNAL_ID 1121; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4191; ORIGINAL_PRECURSOR_SCAN_NO 4189 Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

4-(2,3-dichlorophenyl)-5,7-dihydro-2-methyl-5-oxo-Furo[3,4-b]pyridine-3-carboxylic acid

C15H9Cl2NO4 (336.9909)

HTS 01037

C14H11NO5S2 (337.0079)

HTS01037 is an inhibitor of fatty acid binding; and a competitive antagonist of protein-protein interactions mediated by AFABP/aP2 with a Ki of 0.67 μM.

1,1-DIOXOBENZO[B]THIOPHEN-2-YLMETHYL N-SUCCIMIDYL CARBONATE

C14H11NO7S (337.0256)

4-(Bromomethyl)-N,N-diphenylaniline

C19H16BrN (337.0466)

2,4-Dichloro-5-(1-piperidinylsulfonyl)benzoic acid

C12H13Cl2NO4S (336.9942)

3-FLUORO-2-IODOPHENYL N,N-DIETHYLCARBAMATE

C11H13FINO2 (336.9975)

N-(4-acetylphenyl)-2-(2,4-dichlorophenoxy)acetamide

C16H13Cl2NO3 (337.0272)

benzoylprop

C16H13Cl2NO3 (337.0272)

1-[(3,4-dichlorophenyl)methylamino]cyclohexane-1-carboxylic acid

C14H18Cl3NO2 (337.0403)

tetrasodium,2-(1,2-dicarboxylatoethylamino)butanedioate

C8H7NNa4O8 (336.9762)

(Ferrocenylmethyl)trimethylammonium Bromide

C14H20BrFeN (337.0128)

4-{[3-(Trifluoromethyl)pyridin-2-yl]oxy}benzenesulfonyl chloride

C12H7ClF3NO3S (336.9787)

Methyl 1-(5-bromopyridin-2-yl)-5-(tert-butyl)-1H-pyrazole-4-carboxylate

C14H16BrN3O2 (337.0426)

1-[(2,4-dichlorophenyl)methylamino]cyclohexane-1-carboxylic acid

C14H18Cl3NO2 (337.0403)

tert-Butyl (2-fluoro-4-iodophenyl)carbamate

C11H13FINO2 (336.9975)

tris(cyclopentadienyl)neodymium

C15H15Nd (337.0251)

5-(2-CHLORO-6-METHYLPYRIMIDIN-4-YL)-4-(4-CHLOROPHENYL)-4H-1,2,4-TRIAZOLE-3-THIOL

C13H9Cl2N5S (336.9956)

ethyl 3-bromo-7-(trifluoromethyl)imidazo[1,2-a]pyrimidine-6-carboxylate

C10H7BrF3N3O2 (336.9674)

Benzyl 2,4-dichloro-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate

C15H13Cl2N3O2 (337.0385)

h-8 dihydrochloride

C12H17Cl2N3O2S (337.0418)

1-(4-CHLORO-3-NITROPHENYL)-2-PHENYLETHANONE

C17H11ClF3NO (337.0481)

2-BENZOTHIAZOLYL-3-(4-CARBOXY-2-METHOXYPHENYL)-5-[4-(2-SULFOETHYLCARBAMOYL)PHENYL]-2H-TETRAZOLIUM

C10H16N3O6PS (337.0497)

ETHYL 5-BROMO-3-(2-CARBOXY-VINYL)-1H-INDOLE-2-CARBOXYLATE

C14H12BrNO4 (336.995)

5-Bromo-3-methoxy-2-(pyridin-4-ylmethoxy)benzoic acid

C14H12BrNO4 (336.995)

3-[[1-(3,4-dichlorophenyl)ethylideneamino]oxymethyl]benzoic acid

C16H13Cl2NO3 (337.0272)

4-nitrophenyl-beta-d-glucuronic acid, sodium salt

C12H12NNaO9 (337.041)

tert-Butyl (4-fluoro-2-iodophenyl)carbamate

C11H13FINO2 (336.9975)

H-Gly-Gly-βNA · HBr

C14H16BrN3O2 (337.0426)

BIS(TRICYCLOHEXYLPHOSPHINE)-3-PHENYL-1H-INDEN-1-YLIDENERUTHENIUM(II)DICHLORIDE

C12H7ClF3NO3S (336.9787)

5-Bromo-N-(4-methoxybenzyl)-3-nitropyridin-2-amine

C13H12BrN3O3 (337.0062)

Benzyl 2,4-dichloro-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate

C15H13Cl2N3O2 (337.0385)

Methyl 2-(5-iodo-3-nitropyridin-2-ylamino)acetate

C8H8IN3O4 (336.956)

1-[(3-Bromo-1H-pyrrolo[2,3-b]pyridin-2-yl)methyl]-4-piperidinecar boxylic acid

C14H16BrN3O2 (337.0426)

Neodymium acetate,Neodymium(III) acetate hydrate

C6H11NdO7 (336.9582)

6-chloro-N-cyclopentyl-5-iodo-2-methylpyrimidin-4-amine

C10H13ClIN3 (336.9843)

2,3-Dideoxy-5-iodocytidine

C9H12IN3O3 (336.9923)

ethyl 2-(broMoMethyl)-8-cyano-7-MethoxyiMidazo[1,2-a]pyridine-3-carboxylate

C13H12BrN3O3 (337.0062)

N-( 4-Bromophenyl)-N-(4-methylphenyl)aniline

C19H16BrN (337.0466)

1-(4-(5-Bromopyridin-2-yl)piperazin-1-yl)-2,2,2-trifluoroethanone

C11H11BrF3N3O (337.0038)

(5r)-3-(3-fluoro-4-iodophenyl)-5-hydroxymethyloxazolidin-2-one

C10H9FINO3 (336.9611)

4-[(4-CHLORO-2,5-DIMETHYLPHENYL)THIO]-3-NITROBENZOIC ACID

C15H12ClNO4S (337.0176)

5-(3-IODOPROPOXY)-2-NITROBENZYL ALCOHOL

C10H12INO4 (336.9811)

Ethyl 3-[(E)-2-Amino-1-Cyanoethenyl]-6,7-Dichloro-1-Methyl-1h-Indole-2-Carboxylate

C15H13Cl2N3O2 (337.0385)

N-[1-(4-Bromophenyl)ethyl]-5-fluoro salicylamide

C15H13BrFNO2 (337.0114)

Sudoxicam

C13H11N3O4S2 (337.0191)

C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic

Clodanolene

C14H9Cl2N3O3 (337.0021)

C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant

3-[(5Z)-5-[(4-ethoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid

C15H15NO4S2 (337.0442)

3-[(2-Chloro-6-fluorophenyl)methylthio]-4-ethyl-5-(2-furanyl)-1,2,4-triazole

C15H13ClFN3OS (337.0452)

5-[(6-Nitro-1,3-benzodioxol-5-yl)hydrazinylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione

C11H7N5O6S (337.0117)

S-(Methylmercury)-L-Cysteine

C4H9HgNO2S (337.006)

[(2R,3S,4R,5R)-5-(4-carbamoyl-5-oxidoimidazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate

C9H12N3O9P-2 (337.0311)

fenquizone

C14H12ClN3O3S (337.0288)

Versicolorin

C18H9O7- (337.0348)

5-Hydroxycytidine monophosphate

C9H12N3O9P-2 (337.0311)

4-carbamoyl-1-(5-O-phosphonato-beta-D-ribofuranosyl)-1H-imidazol-3-ium-5-olate

C9H12N3O9P-2 (337.0311)

D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D000970 - Antineoplastic Agents D018501 - Antirheumatic Agents D004791 - Enzyme Inhibitors